Navigation Links
First European Patient Treated in CABERNET Trial With Novel Treatment for Wet AMD
Date:11/29/2007

Ophthalmic Clinic in Germany First in Europe To Treat Patients With New

Focused Radiation Therapy

LEIPZIG, Germany, November 29 /PRNewswire/ -- NeoVista, Inc. announced today that the first European patient has been treated in the company's pivotal global clinical trial for its novel beta radiation epiretinal therapy for the wet form of age-related macular degeneration (AMD). Wet AMD is the most progressive form of AMD and one of the leading causes of blindness in the industrialized world for patients over 50. Unlike the current standard of care which requires costly monthly eye injections, NeoVista's investigational therapy delivers a one-time dose of radiation providing a less invasive and potentially more cost-effective treatment option.

The procedure was performed as part of NeoVista's CABERNET (CNV Secondary to AMD Treated with BEta RaditioN Epiretinal Therapy) trial, which seeks to enroll a total of 450 patients (300 in the radiation treatment arm) in approximately 40 sites worldwide to evaluate the efficacy and safety of NeoVista's novel radiation therapy. Patients in the study receive a single treatment with NeoVista's targeted radiation in combination with an injection of Lucentis(R) at the time of radiation delivery to maximize immediate effect.

"We're excited to have the opportunity to try this innovative technique with our patients. NeoVista's targeted radiation treatment may provide us the ability to improve vision for the elderly and dramatically change their quality of life by eliminating frequent eye injections," said Christian Foja, MD Leipzig University Eye Hospital, who performed the procedure.

Peter Wiedemann, MD, who oversees the department at Leipzig University Eye Hospital, echoed Dr. Foja's sentiments. "NeoVista is developing a promising new wet AMD treatment that could also be a cost-effective alternative in Europe," said Dr. Wiedemann. "And without having to perform regular, monthly injections that are quite expensive for our patients, this procedure will allow our specialists to treat more patients and bring down the cost associated with ongoing treatment."

Unlike previous forms of radiation therapies for wet AMD, NeoVista's radiation device delivers the peak dose of radiation directly to the lesion minimizing radiation exposure to the surrounding tissue. The minimally invasive procedure utilizes a device similar in size and appearance to a fountain pen, to deliver a highly focused radiation directly to the area of the retina affected by wet AMD. Importantly for patients, the exposure to radiation is minimal, as the effective dose to the entire body from NeoVista's epiretinal device is comparable to 15 minutes of sun exposure.

"Ultimately, our goal is to restore vision and quality of life to elderly patients who have been stricken with this debilitating disease by liberating them of the burdens associated with existing wet AMD therapies," said John N. Hendrick, President and CEO of NeoVista. "As our clinical trials continue to show positive results, we are getting closer to achieving that goal and delivering a real solution to physicians and patients."

In addition to Germany, locations of CABERNET study sites include the United Kingdom, Spain, Switzerland, Austria, Israel, Brazil, Mexico, Peru, and the United States. The CABERNET study is intended to support eventual filing for regulatory approval to market the product worldwide.

About Wet AMD

Wet AMD occurs when abnormal blood vessels behind the retina start to grow under the macula, where they leak blood and fluid, causing scar tissue to form and vision to become impaired. With wet AMD vision loss may occur faster and be more noticeable than with dry AMD. The longer the abnormal vessels leak or grow, the more detail vision will be lost. The earlier wet AMD is diagnosed, the better the patients' chance of preserving some or much of their central vision.

About NeoVista, Inc.

NeoVista, Inc. is a privately held development-stage medical device company based in Fremont, California. For more information about the company, the clinical trial or this novel wet AMD therapy, please visit the company's Web site at http://www.neovistainc.com.


'/>"/>
SOURCE NeoVista, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... Doctors in Italy, Japan, the UK and the ... associated protein (BAP1) gene and its link to malignant mesothelioma. Surviving Mesothelioma has just ... the full article now. , The studies analyzed for the new report included ...
(Date:5/27/2016)... , May 27, 2016 At present, ... playing in this space know that volatility is what makes ... companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: SNTA ... Inc. (NASDAQ: LPTN ), and Heat Biologics Inc. ... access to the technical alerts for these stocks at: ...
(Date:5/26/2016)... Jersey and READING, England ... Indegene ( http://www.indegene.com ), a leading global ... life science, pharmaceutical and healthcare organisations and TranScrip ... innovative scientific support throughout the product lifecycle, today ... the launch of IntraScience.      (Logo: ...
(Date:5/26/2016)... , May 26, 2016 Despite the ... value in this space. Today,s pre-market research on ActiveWallSt.com directs ... Health Inc. (NASDAQ: RDUS ), Cerus Corp. (NASDAQ: ... ARWR ), and Five Prime Therapeutics Inc. (NASDAQ: ... briefings at: http://www.activewallst.com/ On ...
Breaking Biology Technology:
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
Breaking Biology News(10 mins):